Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States.
Department of Medical Oncology, Dana-Farber Cancer Institute at Harvard Medical School, Boston, Massachusetts 02215, United States.
ACS Nano. 2023 Aug 22;17(16):15231-15253. doi: 10.1021/acsnano.2c12584. Epub 2023 Aug 3.
During the COVID-19 pandemic, mRNA (mRNA) vaccines emerged as leading vaccine candidates in a record time. Nonreplicating mRNA (NRM) and self-amplifying mRNA (SAM) technologies have been developed into high-performing and clinically viable vaccines against a range of infectious agents, notably SARS-CoV-2. mRNA vaccines demonstrate efficient delivery, long-lasting stability, and nonexistent risk of infection. The stability and translational efficiency of transcription (IVT)-mRNA can be further increased by modulating its structural elements. In this review, we present a comprehensive overview of the recent advances, key applications, and future challenges in the field of mRNA-based vaccinology.
在 COVID-19 大流行期间,mRNA(信使核糖核酸)疫苗在创纪录的时间内成为领先的疫苗候选物。非复制信使核糖核酸(NRM)和自我扩增信使核糖核酸(SAM)技术已被开发成针对一系列传染性病原体(尤其是 SARS-CoV-2)的高性能和临床可行的疫苗。mRNA 疫苗表现出高效的传递、长期稳定和不存在感染风险。通过调节其结构元件,可以进一步提高转录(IVT)-mRNA 的稳定性和翻译效率。在这篇综述中,我们全面介绍了基于 mRNA 的疫苗学领域的最新进展、关键应用和未来挑战。